Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Biome Australia to Commence Domestic Production of Activated Probiotics Range
Biome Australia moves to onshore production of Activated Probiotics, targeting margin rise from 61% toward 65%+ as inventory and lead times shrink.
Latest Stories — SECTOR DESK
Vitrafy Life Sciences Strikes US Partnership to Promote Cryopreservation Ecosystem for Red Blood Cells
Vitrafy inks US Vitalant pact to deploy next-gen cryopreservation for red blood cells as glycerol tech ends by 2027; signals early market traction.
Austco Healthcare Projects Strong FY26 Growth Driven by US Rollout and New Contracts
Austco Healthcare forecasts FY26 revenue A$90-95m and NPAT up 52-58%, led by US Pulse Mobile rollout to 180 hospitals and new contracts.
Memphasys Signs Distribution Deal for Felix Fertility Device into IVF Clinics throughout Vietnam
Memphasys inks $530,000 Vietnam deal to distribute Felix fertility device through TMSC Vietnam, marking first SE Asia partnership and rapid IVF market expansion.
Emyria Poised for Operational Boost as TGA Broadens Psych-Therapy Prescriber Access
Emyria is set to accelerate recruitment as TGA broadens Authorised Prescriber roles for psychedelic therapy, boosting Empax network expansion into H2 2026.
Recce Pharmaceuticals Signs Distribution Agreement for R327 Diabetic Foot Gel across MENA
Recce inks 10-year exclusive MENA licensing deal for R327G diabetic foot gel; upfront fees up to $5m, 30% net sales, Phase III data eyed for year-end approval.
EMVision Medical Devices De-Risks Rural Stroke Use Cases with Aeromedical Study
EMVision de-risks rural stroke use with aeromedical feasibility study; First Responder Brain Scanner unaffected by flight, cash reserves of $18.4m.
Noxopharm Studies Confirm Cancer-Fighting Potential of Sofra Platform
Noxopharm data show Sofra's TLR8-boosting oligonucleotides could amplify cancer immunotherapy; US patent backing strengthens breakthrough potential.
NeuroScientific Biopharmaceuticals Reports Positive Results from StemSmart Crohn’s Trial
NeuroScientific reports on StemSmart Crohn’s trial: 80% clinical response in five patients; safe, paving Phase 2 and a potential entry to a US$13.8B market.
Aroa Biosurgery Sets Ambitious FY27 Targets after Exceeding FY26 Guidance
Aroa Biosurgery beats FY26 guidance as Myriad drives revenue 23% YoY; FY27 targets NZ$115-125m, Symphony catalyst; cash-rich, debt-free.
IMEXHS Wins Major Public Tender in Mexico for Aquila+ Platform
IMEXHS wins Mexico tender for Aquila+ AI radiology, adding US$384k ARR and US$50k fee as 20 sites deploy by June 2026; FY25 profitability improves.
Vitrafy Life Sciences Reports Strong US Army Platelet Preservation Results
Vitrafy Life Sciences announces 94% post-thaw platelet recovery with 3% DMSO no-wash protocol, independent validation for frozen platelets.